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Introduction
The 10th anniversary of the ‘Era of Hope’ meeting spon-
sored by the US Department of Defense (DOD) Breast
Cancer Research Program (BCRP) was held in Orlando,
Florida, USA, during 25–28 September 2002. Basic scien-
tists, clinicians, policymakers, breast cancer survivors and
advocates attended the meeting to learn about advance-
ments in breast cancer research. The mix of individuals with
such diverse backgrounds provided a unique atmosphere
to this meeting. Each day of the meeting began with edu-
cational sessions that covered topics from breast pathol-
ogy to epidemiology to technologies for early detection.
Three innovator sessions were held, one on each day, to
present innovative ideas and results that encouraged the
delegates to think creatively about new strategies for
breast cancer. These sessions ranged from the cell biology
of breast cancer and the role of polarity and epigenetics,
given by Mina Bissell (Lawrence Berkeley National Labora-
tory, California, USA) [1,2], through tumor immunology,
presented by Mary Lenora Disis (University of Washington
in Seattle, Seattle, Washington, USA) [3,4], to creative
approaches in problem solving, by Dean Kramer (Segway,
LLC, Manchester, New Hampshire, USA).
An unusual aspect of the conference was interactive ses-
sions conducted in an open-forum format so that members
of the audience and panel members could freely discuss
critical issues to be addressed in the future in breast
cancer research. In addition to keynote and plenary ses-
sions, there were several focused symposia and poster
sessions that highlighted the research of the recipients of
DOD-BCRP grants. An inspirational feature of the meeting
was that scientists and breast cancer advocates co-
chaired the symposia. This reinforced a sense of collabo-
ration between the women who have had breast cancer
and the researchers, a collaboration that should help to
define the important areas that need to be explored and
addressed in breast cancer research. Owing to the exten-
sive amount of research presented, the following report
will include summaries of only a representative sampling of
the excellent science that was presented.
Rodent models of mammary gland
development, tumorigenesis and metastasis
An early educational session presented by Jeffrey M Rosen
(Baylor College of Medicine, Houston, Texas, USA)
focused on the importance of studying normal mammary
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Abstract
The Era of Hope meeting addressed with a multidisciplinary approach the most critical issues in breast
carcinogenesis. The issues that we summarize here include: a) the use of rodent models for the study
of mammary gland development and breast tumorigenesis; b) the effects of stroma on mammary
epithelial differentiation and malignant transformation; c) a further characterization of the interactions
between steroid and growth factor receptors; d) the improvement of technologies for early detection of
breast tumors and the establishment of their progression; and e) the development of vaccines as
potential new therapies against specific tumor markers.
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gland development for understanding how breast cancer
arises. The same molecular events controlling normal
development, when deregulated, result in cancer. In this
overview, Rosen referred to cell polarity, steroid receptors,
growth factors and p53 as crucial factors in mammary
gland development and tumor progression. Quiescent
mammary stem cells with significant regenerative capacity
might have a role in tumorigenesis. In this regard, his recent
publication [5] showed that cells positive for stem cell
antigen-1 represent an enriched population of progenitor
cells and have increased regenerative potential when trans-
planted into cleared fat pads. In addition, several presenta-
tions addressed signaling molecules involved in branching
morphogenesis and mammary tumorigenesis. For example,
Eran Andrechek (Department of Biology, McMaster Univer-
sity Hamilton, Ontario, Canada) showed that conditional
activation of neu under the endogenous promoter resulted
in accelerated lobulo-alveolar development and altered
branching morphogenesis of the mammary gland.
An interactive session brought forward various concerns
about the sufficiency of rodent models for the study of
human mammary tumorigenesis. One concern emerged
from these discussions, namely that current mouse
models are inadequate for the study of metastatic breast
cancer because mouse mammary tumors do not typically
metastasize; neither do the tumors resemble human
pathology. However, one mouse model showing lung
metastasis and tumor recurrence was presented by Susan
Moody (University of Pennsylvania, Philadelphia, Pennsyl-
vania, USA) using transgenic mice that overexpressed neu
under the tetracycline-inducible promoter. Graeme
Hodgson and collaborators (University of California, San
Francisco, California, USA) have used comparative
genomic hybridization to identify specific abnormalities of
genomic copy number leading to metastasis with the use
of two transgenic mouse models, erbB2 and polyomavirus
middle T antigen. These mice develop mammary tumors
that often metastasize to the lung. Marcia Noble (George-
town University, Washington DC, USA) presented a
bitransgenic mouse model in which overexpression of c-
myc and vascular endothelial growth factor (VEGF)
showed increased angiogenesis and metastasis. As an
alternative to mouse models, transgenic rat models are
being developed by Michael Gould (University of Wiscon-
sin, Madison, Wisconsin, USA) because they display
mammary tumor morphology with more resemblance to
human hormone-responsive breast tumors.
Angiogenesis and proteinases
Understanding mechanisms involved in angiogenesis and
finding therapies to inhibit angiogenesis are important
topics in breast cancer research. In a plenary session,
Renata Pasqualini (University of Texas MD Anderson
Cancer Center, Houston, Texas, USA) presented an
approach to determine ‘molecular addresses’ in blood
vessels with an in vivo phage display. Tumor-homing pep-
tides can be designed to deliver therapeutic or imaging
agents directly to the tumor (reviewed in [6]). In addition,
several posters presented data characterizing the role of
VEGF, its receptors, and signaling pathways to uncover
novel ways of disrupting angiogenesis in breast tumor pro-
gression. Proteinases have an integral role in angiogenesis,
because for new blood vessels to form, components of the
extracellular matrix must be degraded and remodeled. There
were several posters characterizing the role of serine pro-
teinases and their inhibitors in breast cancer. Additionally,
there were several presentations on metalloproteinases, in
particular matrix metalloproteinases (MMPs). Data were pre-
sented by the laboratory of Constance Brinckerhoff (Dart-
mouth Medical School, Hanover, New Hampshire, USA)
that characterized the effect of a single nucleotide polymor-
phism occurring in the MMP-1 promoter. Other posters,
such as those presented by the laboratory of Rafael
Fridman (Wayne State University, Detroit, Michigan, USA)
examined the regulation of MMP activation [7].
Stromal influences on mammary epithelium
Stromal effects on mammary epithelial differentiation and
tumor progression were the topic of several presentations.
One of the factors involved in epithelial–stromal communi-
cation is transforming growth factor β (TGFβ). Michael R
Crowley and Rose Serra (University of Cincinnati, Cincin-
nati, Ohio, USA) developed a transgenic mouse model that
expressed a zinc-inducible kinase-defective dominant-
negative TGFβ type II receptor in the mammary stroma.
These mice displayed increased lateral branching, suggest-
ing that TGFβ signaling in the stroma has important effects
on epithelial morphogenesis. Maria Jose Pajares (Lawrence
Berkeley National Laboratory, Berkeley, California, USA)
showed that ionizing radiation at a low dose caused
reduced mammary epithelial apoptosis and p53 activation
in a TGFβ1 heterozygous mouse model in comparison with
wild-type mice. This suggests that TGFβ1 activation in
response to radiation damage can alter cell fate decisions.
A symposium of particular interest was focused on the
effect of stromal–epithelial interactions in breast cancer. In
particular, Hema Parmar (University of California, San
Francisco, California, USA) presented an interesting
model in which human mammary ductal organoids were
co-cultured with human fibroblasts in a collagen type I gel
that was grafted under the renal capsule of female nude
mice. By means of this technique, normal human mammary
morphology was recapitulated. When normal fibroblasts
were replaced by mammary carcinoma-associated fibro-
blasts, aberrant ductal morphology resulted.
Crosstalk between steroid receptors and
growth factor receptors
Some of the new approaches regarding steroid hormones
as therapeutic targets were presented. Geoffrey L Greene55
(University of California, San Francisco, California, USA)
described the use of the synthetic compound (R,R)-5,11-
cis-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol (THC)
as a selective estrogen agonist when bound to estrogen
receptor (ER)α and as an antagonist when bound to ERβ.
The mechanism of ligand discrimination by THC has
recently been published [8]. In contrast, Jennifer Richer
(University of Colorado, Denver, Colorado, USA) pro-
posed that an inappropriate sensitivity to estrogens and
progestins could be due to the overexpression of
members of the Kruppel-like zinc-finger and winged-helix
domain families of transcription factors. These factors
were shown to be upregulated by progesterone in T47D
human breast cancer cells.
In an interactive session, alternative treatments and combi-
natorial therapies targeting growth factor receptor path-
ways to prevent resistance to anti-hormonal therapy were
advocated. Several other presentations were also focused
on the crosstalk between steroids and peptide growth
factors. Richard Pietras (University of California, Los
Angeles, California, USA) described the membrane-asso-
ciated ER that localized to caveola-related structures,
where it interacts with HER-2/neu growth factor receptor.
This interaction produces an acute activation of mitogen-
activated protein kinase and Akt [9], which promotes intra-
cellular signaling for estrogen-mediated proliferation that
could be a new target for antitumor therapy. In contrast, c-
Src tyrosine kinase was proposed by William J Muller
(McMaster University, Hamilton, Ontario, Canada) to
mediate ER phosphorylation and transcriptional activation,
and to be required for normal mammary ductal outgrowth.
In addition, the involvement of AIB1 (amplified in breast
cancer-1), a steroid receptor coactivator, in integrating
signals from steroid hormones and growth factors, as well
as its role in hormone-dependent transcriptional activation
of ER, was discussed in several presentations. These
data, and the fact that AIB1 overexpression leads to
altered ductal growth and breast cancer, make this co-
activator a potential target for therapy and breast cancer
prevention.
New technologies applied to understanding
breast tumor progression
Ductal carcinoma in situ (DCIS) occurs in about 30% of
breast tumors. However, many questioned whether DCIS
is currently being overtreated. To permit better diagnosis
and prediction of the progression of DCIS, improved
imaging methods to determine the grade, extent and
margins of the tumor are crucial. A computer-assisted
three-dimensional microscopy system to model DCIS
lesions, using fully sectioned tissue samples, is being
developed by Carlos Ortiz de Solórzano (Lawrence Berke-
ley National Laboratory, Berkeley, California, USA). An
improvement in magnetic resonance imaging (MRI) to
provide better contrast, texture and edge delineation than
conventional MRI is being developed by GS Karczmar
(University of Chicago, Chicago, Illinois, USA) and by
Savannah Partridge (University of California, San Fran-
cisco, California, USA).
Other novel imaging methods being developed include
near-infrared spectroscopy (Hanli Liu, University of Texas
Southwestern Medical Center, Dallas, Texas, USA), laser
optoacoustic tomography (Alexander Oraevsky and
Sergey Solomatin, University of Texas Medical Branch,
Galveston, Texas, USA), and breast cancer radars and
microwave imaging to contrast high water content in
tumors and low water content in normal tissues (Jack
Bridges, Mt Prospect, Illinois, USA). In contrast, gene
expression profiling using cDNA arrays (discussed by
Dennis Sgroi, Harvard Medical School, Boston, Massa-
chusetts, USA) and proteomics (discussed by Patricia
Steeg, National Cancer Institute, NIH, Bethesda, Mary-
land, USA) are other potential tools for determining tumor
grade and progression. David Botstein (Stanford Univer-
sity, Palo Alto, California, USA) highlighted the use of
microarray technology in the characterization of breast
cancers. Results from the array data can potentially be
used to determine types of therapy.
Development of vaccines against breast cancer
In several immunology sessions, data were presented in
connection with the possibility of developing vaccines to
increase T-cell response against tumor cells. Some
groups have developed specific vaccines targeting ErbB-
2/HER-2/neu, seeking to change tumor tolerance and
improve antigen presentation in mouse models. AM Ercol-
ini (The Johns Hopkins University School of Medicine, Bal-
timore, Maryland, USA) has characterized a major
histocompatibility complex class I epitope in a rat neu-N
transgenic mouse model that accomplished both aims. By
genetically linking IgG Fc fragments and heat shock pro-
teins to the rat neu gene, Xue F Huang (Baylor College of
Medicine, Houston, Texas, USA) showed enhanced
antigen presentation by receptor-mediated internalization
of dendritic cells. Another strategy with a gene-based
approach to the induction of a specific T-cell response
against Her-2/neu antigen in mice was presented by
Lawrence Lachman (University of Texas, MD Anderson
Cancer Center, Houston, Texas, USA) and Brian Long
(University of North Carolina, Chapel Hill, North Carolina,
USA).
DNA repair in breast cancer
Genetic instability is a common feature of human cancers.
Thus, it is important to understand mechanisms involved in
DNA repair. Mark Brenneman (University of New Mexico,
Albuquerque, New Mexico, USA) and Yi-Ching Lio
(Lawrence Berkeley National Laboratory, Berkeley, Califor-
nia, USA) found that disruption of the interaction between
BRCA2 (breast cancer suppressor gene 2) and RAD51
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(part of a multiprotein complex that participates in homolo-
gous recombination) significantly decreased homologous
recombinational repair. Jean Latimer (University of Pitts-
burgh, Pittsburgh, Ohio, USA) showed that both breast
tumor and adjacent non-tumor tissue manifested a defi-
ciency of nucleotide excision repair, and that proteins with
DNA helicase activity might be involved. Guo-Min Li (Uni-
versity of Kentucky, Lexington, Kentucky, USA) observed
genetic and epigenetic alterations of two mismatch repair
genes, hMSH2 and hMLH1, in sporadic breast tumors
with microsatellite instability.
Conclusion
A main objective of the DOD-BCRP Meeting is to bring
together in a friendly and interactive environment a multi-
disciplinary spectrum of people with the common aim of
understanding, preventing and controlling breast cancer.
This format was clearly successful; this multidisciplinary
interaction should continue in the future, to facilitate early
detection and to improve therapies for breast cancer.
Here we have presented a summary of some relevant sym-
posia and posters presented at the conference. A com-
plete list of abstracts can be found at http://cdmrp.army.
mil/bcrp/era/default.htm.
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